Related Experiment Video
Updated: Aug 9, 2026
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
[Survival analysis for patients with hepatocellular carcinoma according to stage, liver function and treatment
Kyung Woo Park1, Joong Won Park, Sang Hyung Cho
1Center for Liver Cancer, National Cancer Center, Goyang, Korea.
Insights
This study analyzed Hepatocellular carcinoma (HCC) survival rates in Korea, finding that serum AFP, portal vein thrombosis, Child-Pugh classification, and HCC stage are key prognostic factors. These findings aid in developing better treatment strategies for HCC patients.
Area of Science:
- Hepatology
- Oncology
- Clinical Research
Context:
- Hepatocellular carcinoma (HCC) is a significant health concern in Korea, characterized by poor patient prognosis.
- Assessing current treatment outcomes is crucial for improving survival rates.
Purpose:
- To analyze the three-year survival rate (3-YSR) and identify prognostic factors for HCC patients in Korea.
- To evaluate the effectiveness of different treatment modalities based on disease stage and patient classification.
Summary:
- A study of 905 HCC patients in Korea (2000-2003) revealed a median survival of 15.3 months and an overall 3-YSR.
- Modified UICC staging showed limitations in differentiating between stages I/II and IVa/IVb for 3-YSR.
- Independent prognostic factors identified include serum AFP, portal vein thrombosis, Child-Pugh classification, and HCC stage.
Impact:
- The study provides valuable data for assessing HCC treatment results in Korea.
- Findings will inform the development of more effective treatment strategies for Hepatocellular carcinoma.
Background/Aims:
Hepatocellular carcinoma (HCC) is 3rd leading cause of cancer in Korea and the prognosis for HCC patients is poor. For assessing the present treatment outcome, this study analyzed the three-year survival rate (3-YSR) and the prognostic factors for patients with HCC in Korea.
Methods:
Between November 2000 and December 2003, 905 patients with HCC who were diagnosed and treated at the National Cancer Center Korea were enrolled in this study. The clinical variables, tumor characteristics and survival periods were analyzed.
Results:
The mean age of all patients was 56.2+/-10.3 years and 732 (80.9%) patients were male (M:F=4.2:1). 508 (56.1%) patients died and the median survival period was 15.3 months. The overall 3-YSR of the patients with modified UICC stage I, II, III, IVa and IVb were 67.4%, 65.2%, 30.7%, 9.0% and 5.0%, respectively. The modified UICC stage could not differentiate stage I from II, and stage IVa from IVb, on the 3-YSR. The 3-YSR of the Child-Pugh class A patients with modified UICC stage I or II was 85.4% by surgical resection and it was 69.6% by transcatheter chemoembolization (TACE), respectively (P= .461), and those values for patients with stage III were 49.2% and 36.8%, respectively (P=.081). As compared with systemic chemotherapy or conservative therapy, TACE increased the survival rate more for the Child-Pugh class A patients with stage IV. The independent prognostic factors were serum AFP, portal vein thrombosis, the Child-Pugh classification and the stage of HCC.
Conclusions:
This follow-up study will be helpful in assessing the results of treatments for HCC and it will provide data for the establishment of a more effective treatment strategy.
Related Concept Videos
01:21Cancer Survival Analysis
01:20Comparing the Survival Analysis of Two or More Groups
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:24Kaplan-Meier Approach